General Information of Drug (ID: DM0PSCF)

Drug Name
Ro 20-1724 Drug Info
Synonyms
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; RO 20-1724; 29925-17-5; 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one; ro-20-1724; Ro 201724; CHEMBL18701; 4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-; RO-201724; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-, (+-)-; 4-(3-butoxy-4-methoxy-benzyl)imidazolidin-2-one; 34185-37-0; 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone; SR-01000075647; keratan sulfate I; Keratan sulphate I; Naphthoquinone analogs
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Terminated [1]
Cross-matching ID
PubChem CID
5087
ChEBI ID
CHEMBL18701
CAS Number
CAS 29925-17-5
TTD Drug ID
DM0PSCF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MX-7065 DMP26BW Solid tumour/cancer 2A00-2F9Z Terminated [5]
3-isopropyl-4-(phenylthio)naphthalene-1,2-dione DMJZEMB Discovery agent N.A. Investigative [6]
4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione DMQA0EJ Discovery agent N.A. Investigative [6]
1-dodecyl-1H-indole-2,3-dione DMK6BWV Discovery agent N.A. Investigative [7]
3-isopropyl-4-phenylnaphthalene-1,2-dione DMYZCWX Discovery agent N.A. Investigative [6]
NSC-95397 DMX0TAM Discovery agent N.A. Investigative [8]
3-isopropyl-4-(phenylamino)naphthalene-1,2-dione DMHAJ6W Discovery agent N.A. Investigative [6]
3-isopropylnaphthalene-1,2-dione DM46ID2 Discovery agent N.A. Investigative [6]
2-(1-dodecyl-1H-indol-3-yl)acetic acid DMF2XHZ Discovery agent N.A. Investigative [7]
(E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid DMI146O Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Phosphodiesterase 4 (PDE4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [9]
Oxtriphylline DMLHSE3 Cough MD12 Approved [10]
Roflumilast DMPGHY8 Asthma CA23 Approved [11]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [12]
crisaborole DMNVKU6 Atopic dermatitis EA80 Approved [13]
Arofylline DM84AD1 Chronic obstructive pulmonary disease CA22 Phase 3 [14]
ARQ-151 DML61S4 Atopic dermatitis EA80 Phase 3 [15]
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [16]
ONO-6126 DMRT28X Chronic obstructive pulmonary disease CA22 Phase 2 [14]
E6005 DM1S489 Atopic dermatitis EA80 Phase 2 [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [18]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [19]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [20]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [21]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [22]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [23]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [24]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [25]
Epinephrine DM3KJBC Acute asthma CA23 Approved [26]
Chlorthalidone DM4DMBT Edema MG29 Approved [27]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
M-phase inducer phosphatase 1 (MPIP1) TTLZS4Q MPIP1_HUMAN Inhibitor [2]
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Renin (REN) OT52GZR2 RENI_HUMAN Protein Interaction/Cellular Processes [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5258).
2 Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000 Sep;106(6):753-61.
3 Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol. 1993 May;100(5):681-4.
4 Beta-adrenergic regulation of renin expression in differentiated U-937 monocytic cells. Biochem Pharmacol. 1997 Jun 15;53(12):1883-8. doi: 10.1016/s0006-2952(97)00058-0.
5 Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).
6 Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
7 Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3.
8 Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4330-4.
9 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
12 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
13 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
14 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
15 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
16 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
17 Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.
18 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
19 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
20 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
21 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
22 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
23 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
24 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
25 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
26 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
27 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.